Multiple Cancer Clinical Trials

Kidney Cancer and
Other Solid Tumors (ARC-20)

Overview

A multicenter, open-label Phase 1 study to evaluate the safety, biomarkers and pharmacokinetic (PK), pharmacodynamic (PD) and preliminary clinical activity of AB521 as a monotherapy for advanced solid tumor malignancies (dose escalation) and clear cell renal cell carcinoma (dose expansion).

Key Eligibility Criteria

Male or female participants over 18 years old.
At least one measurable lesion per RECIST guidance.
Disease-specific inclusion criteria for dose escalation: Any pathologically confirmed solid tumor type where no other treatment options are available.
Disease-specific inclusion criteria for dose expansion: Histologically confirmed ccRCC; prior treatment in the metastatic setting (either individually or in combination) with an anti-PD-1 therapy and a tyrosine kinase inhibitor; and no prior treatment with a HIF-2α-targeted therapy.

ARC-20 Clinical Trial Locations

clinicaltrials.gov

Multiple Cancer Types
(AB308 + zimberelimab; ARC-12 study)

Overview

A Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab in participants with advanced malignancies.

Key Eligibility Criteria

Participants must have performance score of 0 or 1 with measurable disease as per radiographic evaluation
Disease specific criteria for dose escalation includes participants with any type of solid tumor for which no treatment is currently available, or participants with non-Hodgkin Lymphoma that has progressed on prior chemotherapy and are unable to receive stem cell transplant or adoptive cell transfer. Participants may have received up to 5 prior anti-cancer therapies and an unlimited number of prior hormonal therapies.
No prior treatments with an anti-TIGIT antibody, active or prior autoimmune disease that required treatment in past 3 years or prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.

AB308 + zimberelimab Clinical Trial Locations

clinicaltrials.gov

Multiple Cancer Types Trials

Kidney Cancer and
Other Solid Tumors (ARC-20)

Multiple Cancer Types
(AB308 + zimberelimab; ARC-12 study)

Explore More

Multiple Cancer Types Trials

Kidney Cancer and Other Solid Tumors (ARC-20)

Multiple Cancer Types (AB308 + zimberelimab; ARC-12 study)

Explore More

Kidney Cancer and
Other Solid Tumors (ARC-20)

Multiple Cancer Types
(AB308 + zimberelimab; ARC-12 study)